menu
    • menu
    [{"orgOrder":0,"company":"Viela Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viela Bio Announces Positive Interim Results from a Phase 1b Study of VIB7734 in Patients with Cutaneous Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"VIB7734","moa":"IL-7","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Viela Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viela Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Viela Bio \/ Not Applicable"},{"orgOrder":0,"company":"Viela Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viela Bio Announces Data Presentations at the 8Th Joint Actrims-Ectrims Meeting, Ms Virtual 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Inebilizumab","moa":"CD19","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Viela Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viela Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viela Bio \/ Not Applicable"},{"orgOrder":0,"company":"Viela Bio","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"$3,005.0 million","upfrontCash":"$3,005.0 million","newsHeadline":"Horizon Therapeutics to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Acquisition","leadProduct":"Inebilizumab","moa":"CD19","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Viela Bio","amount2":3.0099999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":3.0099999999999998,"dosageForm":"Intravenous Injection","sponsorNew":"Viela Bio \/ Horizon Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Viela Bio \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Viela Bio","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"$3,005.0 million","upfrontCash":"$3,005.0 million","newsHeadline":"Horizon Therapeutics Plc Completes Acquisition of Viela Bio, Inc.","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Acquisition","leadProduct":"Inebilizumab","moa":"CD19","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Viela Bio","amount2":3.0099999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":3.0099999999999998,"dosageForm":"Intravenous Injection","sponsorNew":"Viela Bio \/ Horizon Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Viela Bio \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Viela Bio","sponsor":"Ventyx Biosciences","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inflammatory Disease Biotech Ventyx Biosciences Files for A $100 Million IPO","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Public Offering","leadProduct":"VTX958","moa":"Allosteric TYK2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Viela Bio","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Viela Bio \/ Viela Bio","highestDevelopmentStatusID":"6","companyTruncated":"Viela Bio \/ Viela Bio"}]

    Find Clinical Drug Pipeline Developments & Deals by Viela Bio

    Menu

    Viela Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Viela Bio

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Viela Bio

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VTX958

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Recipient : Ventyx Biosciences

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Inflammatory Disease Biotech Ventyx Biosciences Files for A $100 Million IPO

                            Details : VTX958, an oral, selective clinical-stage tyrosine kinase type 2 inhibitor that it believes has the potential to address a broad range of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus.

                            Brand Name : VTX958

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 29, 2021

                            Lead Product(s) : VTX958

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Recipient : Ventyx Biosciences

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Viela Bio

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Viela Bio

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inebilizumab

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Horizon Therapeutics

                            Deal Size : $3,005.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Horizon Therapeutics Plc Completes Acquisition of Viela Bio, Inc.

                            Details : Horizon Therapeutics gets UPLIZNA, first and only FDA-approved B-cell-depleting humanized monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder.

                            Brand Name : Uplizna

                            Molecule Type : Large molecule

                            Upfront Cash : $3,005.0 million

                            March 15, 2021

                            Lead Product(s) : Inebilizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Horizon Therapeutics

                            Deal Size : $3,005.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Viela Bio

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Viela Bio

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inebilizumab

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Horizon Therapeutics

                            Deal Size : $3,005.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Horizon Therapeutics to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Dis...

                            Details : Horizon adds UPLIZNA® (inebilizumab-cdon) to its commercial rare disease medicine portfolio. The acquisition Adds deep, mid-stage biologics pipeline focused primarily on autoimmune and severe inflammatory diseases.

                            Brand Name : Uplizna

                            Molecule Type : Large molecule

                            Upfront Cash : $3,005.0 million

                            February 01, 2021

                            Lead Product(s) : Inebilizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Horizon Therapeutics

                            Deal Size : $3,005.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Viela Bio

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Viela Bio

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inebilizumab

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Viela Bio Announces Data Presentations at the 8Th Joint Actrims-Ectrims Meeting, Ms Virtual 2020

                            Details : First poster will highlights study results in AQP4-IgG seronegative patients in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.

                            Brand Name : Uplizna

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 03, 2020

                            Lead Product(s) : Inebilizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Viela Bio

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Viela Bio

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VIB7734

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Viela Bio Announces Positive Interim Results from a Phase 1b Study of VIB7734 in Patients with Cutaneous Lupus...

                            Details : The interim findings indicated safety and tolerability comparable to placebo control across all cohorts, potent depletion of pDC both in peripheral blood and in inflamed CLE skin lesion biopsies in cohort 2, and dose-dependent reduction in CLASI after tr...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 14, 2020

                            Lead Product(s) : VIB7734

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth